CRISPR Therapeutics clears a key chart level, shares trade higher on NASDAQ

CRISPR Therapeutics moves above its 50-day moving average in recent NASDAQ trade, putting the gene-editing specialist on chart watchers' radar while analysts maintain a constructive long-term view.

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-23, 22:15.

CRISPR Therapeutics (CH0334081137) sits on the NASDAQ with renewed technical momentum. On June 5, 2026 the shares moved above their 50-day moving average, a level highlighted by Tickeron in a recent chart update. Tickeron chart commentary on CRSP

The 50-day line reclaimed

Tickeron reports that on June 5 CRISPR Therapeutics shares closed above their 50-day moving average, marking a technical inflection for the biotechnology stock. Detailed Tickeron signal for CRSP As of June 23, 2026 at 11:40 a.m. Eastern, the same source quotes the shares at 55.59 dollars, up 2.26 percent on the day, with a market capitalization of 5.35 billion dollars.

The move above the 50-day line comes after a period of consolidation, with CRISPR Therapeutics trading in the mid-50 dollar range on several platforms that relay delayed NASDAQ prices. While intraday trading signals on Tickeron flag a short-term Buy stance, the longer-term picture is shaped above all by analyst expectations and the company’s pipeline.

Analyst targets and consensus picture

Stockscan.io aggregates analyst forecasts and calculates an average 30-day price target for CRISPR Therapeutics at 131.40 dollars, based on several houses covering the NASDAQ-listed biotech. This implies a potential upside of roughly 142 percent from a reference price of 54.27 dollars used in the Stockscan analysis.

Within that distribution, the highest analyst target stands at 152.62 dollars and the lowest at 110.17 dollars, again according to Stockscan’s compilation of Wall Street estimates. Analyst forecast summary for CRSP on Stockscan MarketBeat’s news and data pages, which track upgrades, downgrades and earnings trends for CRSP, also reflect a constructive bias in recent analyst commentary, even if individual ratings vary across firms.

The product behind the stock

CRISPR Therapeutics is a Swiss-American biopharmaceutical group focused on gene-editing therapies, using its proprietary CRISPR/Cas9 platform. A flagship product is Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, developed together with Vertex Pharmaceuticals.

Where the stock trades today

CRISPR Therapeutics shares (CH0334081137) trade on June 23, 2026 at 11:40 a.m. Eastern on NASDAQ at 55.59 dollars. This price level reflects the latest intraday quote cited by Tickeron for the biotech stock.

CRISPR Therapeutics at a glance

• Company: CRISPR Therapeutics AG
• ISIN: CH0334081137
• WKN: A2ATW2
• Ticker: CRSP
• Trading venue: NASDAQ
• Price (as of 2026-06-23, 11:40): 55.59 USD
• Market cap: 5.35 billion USD (as of 2026-06-23)
• Sector / industry: Biotechnology
• Index membership: NASDAQ Biotechnology-related indices (via sector classification)
• Next earnings date: 2026-08-10

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any kind. Figures and dates are based on sources cited and may change; investors should consult official filings and professional advisers before making investment decisions.